{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:09:30Z","timestamp":1790633370501,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070227"],"award-info":[{"award-number":["82070227"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research Center for Translational Medicine","award":["NRCTM (SH)-2021-10"],"award-info":[{"award-number":["NRCTM (SH)-2021-10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04086-y","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:01:10Z","timestamp":1746183670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring secondary extramedullary myeloma disease: a five-predictor scoring system with spotlight on double-hit cytogenetics"],"prefix":"10.1186","volume":"23","author":[{"given":"Yi","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyan","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"4086_CR1","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"4086_CR2","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98:1540\u20139.","journal-title":"Am J Hematol"},{"key":"4086_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2013.094409","volume":"99","author":"L Pour","year":"2014","unstructured":"Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99:360\u20134.","journal-title":"Haematologica"},{"key":"4086_CR4","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/leu.2011.29","volume":"25","author":"KD Short","year":"2011","unstructured":"Short KD, Rajkumar SV, Larson D, Buadi F, Hayman S, Dispenzieri A, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25:906\u20138.","journal-title":"Leukemia"},{"key":"4086_CR5","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3324\/haematol.2012.078519","volume":"97","author":"J Blade","year":"2012","unstructured":"Blade J, de Larrea CF, Rosinol L. Extramedullary involvement in multiple myeloma. Haematologica. 2012;97:1618\u20139.","journal-title":"Haematologica"},{"key":"4086_CR6","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjh.17925","volume":"196","author":"M Stork","year":"2022","unstructured":"Stork M, Sevcikova S, Minarik J, Krhovska P, Radocha J, Pospisilova L, et al. Identification of patients at high risk of secondary extramedullary multiple myeloma development. Br J Haematol. 2022;196:954\u201362.","journal-title":"Br J Haematol"},{"key":"4086_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjh.13382","volume":"169","author":"C Varga","year":"2015","unstructured":"Varga C, Xie W, Laubach J, Ghobrial IM, O\u2019Donnell EK, Weinstock M, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015;169:843\u201350.","journal-title":"Br J Haematol"},{"key":"4086_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ejh.13217","volume":"102","author":"R Jimenez-Segura","year":"2019","unstructured":"Jimenez-Segura R, Granell M, Gironella M, Abella E, Garcia-Guinon A, Oriol A, et al. Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed \/ refractory multiple myeloma. Eur J Haematol. 2019;102:389\u201394.","journal-title":"Eur J Haematol"},{"key":"4086_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41375-021-01343-w","volume":"36","author":"T Jelinek","year":"2022","unstructured":"Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, et al. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease. Leukemia. 2022;36:288\u201391.","journal-title":"Leukemia"},{"key":"4086_CR10","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41375-021-01433-9","volume":"36","author":"S Zanwar","year":"2022","unstructured":"Zanwar S, Ho M, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, et al. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia. 2022;36:873\u20136.","journal-title":"Leukemia"},{"key":"4086_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755866","volume":"12","author":"Y Que","year":"2021","unstructured":"Que Y, Xu M, Xu Y, Almeida VDF, Zhu L, Wang Z, et al. Anti-BCMA CAR-T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. Front Immunol. 2021;12: 755866.","journal-title":"Front Immunol"},{"key":"4086_CR12","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"4086_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","volume":"24","author":"R Mina","year":"2023","unstructured":"Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023;24:64\u201376.","journal-title":"Lancet Oncol"},{"key":"4086_CR14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","volume":"97","author":"FM Ross","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O\u2019Connor S, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97:1272\u20137.","journal-title":"Haematologica"},{"key":"4086_CR15","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-024-12077-0","volume":"24","author":"Y Tao","year":"2024","unstructured":"Tao Y, Jin S, Yang D, Pan M, Ouyang W, Liu Y, et al. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma. BMC Cancer. 2024;24:406.","journal-title":"BMC Cancer"},{"key":"4086_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","volume":"34","author":"M Bhutani","year":"2020","unstructured":"Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1\u201320.","journal-title":"Leukemia"},{"key":"4086_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","volume":"36","author":"S Sevcikova","year":"2019","unstructured":"Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 2019;36:32\u20139.","journal-title":"Blood Rev"},{"key":"4086_CR18","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","volume":"24","author":"G Ledergor","year":"2018","unstructured":"Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, et al. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med. 2018;24:1867\u201376.","journal-title":"Nat Med"},{"key":"4086_CR19","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/s12276-022-00884-z","volume":"54","author":"SH Jung","year":"2022","unstructured":"Jung SH, Park SS, Lim JY, Sohn SY, Kim NY, Kim D, et al. Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness. Exp Mol Med. 2022;54:1967\u201378.","journal-title":"Exp Mol Med"},{"key":"4086_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"O Zavidij","year":"2020","unstructured":"Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, et al. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nat Cancer. 2020;1:493\u2013506.","journal-title":"Nat Cancer"},{"key":"4086_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27:491\u2013503.","journal-title":"Nat Med"},{"key":"4086_CR22","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D'Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"4086_CR23","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125:2068\u201374.","journal-title":"Blood"},{"key":"4086_CR24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/1078-0432.CCR-19-0694","volume":"26","author":"D Ryu","year":"2020","unstructured":"Ryu D, Kim SJ, Hong Y, Jo A, Kim N, Kim HJ, et al. Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion. Clin Cancer Res. 2020;26:935\u201344.","journal-title":"Clin Cancer Res"},{"key":"4086_CR25","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","volume":"38","author":"T Jelinek","year":"2024","unstructured":"Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024;38:1323\u201333.","journal-title":"Leukemia"},{"key":"4086_CR26","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/ajh.26261","volume":"96","author":"S Richard","year":"2021","unstructured":"Richard S, Chari A, Delimpasi S, Simonova M, Spicka I, Pour L, et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol. 2021;96:1120\u201330.","journal-title":"Am J Hematol"},{"key":"4086_CR27","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1172\/JCI88169","volume":"128","author":"Y Kawano","year":"2018","unstructured":"Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, et al. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018;128:2487\u201399.","journal-title":"J Clin Invest"},{"key":"4086_CR28","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3324\/haematol.2022.282399","volume":"108","author":"M Thomas","year":"2023","unstructured":"Thomas M, Li J, King K, Persaud AK, Duah E, Vangundy Z, et al. PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant. Haematologica. 2023;108:2155\u201366.","journal-title":"Haematologica"},{"key":"4086_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.846310","volume":"13","author":"A Gilchrist","year":"2022","unstructured":"Gilchrist A, Echeverria SL. Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma. Front Endocrinol (Lausanne). 2022;13: 846310.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4086_CR30","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41556-021-00766-y","volume":"23","author":"J Frede","year":"2021","unstructured":"Frede J, Anand P, Sotudeh N, Pinto RA, Nair MS, Stuart H, et al. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol. 2021;23:1199\u2013211.","journal-title":"Nat Cell Biol"},{"key":"4086_CR31","first-page":"1657","volume":"19","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Hu L, Guo Y, Xiao Z, Xu Q, Tong X. FBW7 in hematological tumors. Oncol Lett. 2020;19:1657\u201364.","journal-title":"Oncol Lett"},{"key":"4086_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.757","volume":"12","author":"H He","year":"2022","unstructured":"He H, Li Z, Lu J, Qiang W, Jiang S, Xu Y, et al. Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma. Clin Transl Med. 2022;12: e757.","journal-title":"Clin Transl Med"},{"key":"4086_CR33","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3324\/haematol.2012.067272","volume":"98","author":"RJ Pessoa de Magalhaes","year":"2013","unstructured":"Pessoa de Magalhaes RJ, Vidriales MB, Paiva B, Fernandez-Gimenez C, Garcia-Sanz R, Mateos MV, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica. 2013;98:79\u201386.","journal-title":"Haematologica."},{"key":"4086_CR34","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/MOH.0000000000000259","volume":"23","author":"S Manier","year":"2016","unstructured":"Manier S, Kawano Y, Bianchi G, Roccaro AM, Ghobrial IM. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Curr Opin Hematol. 2016;23:426\u201333.","journal-title":"Curr Opin Hematol"},{"key":"4086_CR35","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1182\/blood.2020005795","volume":"136","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhao D, Xian M, Wang Z, Bi E, Su P, et al. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood. 2020;136:2557\u201373.","journal-title":"Blood"},{"key":"4086_CR36","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1038\/s41388-022-02376-w","volume":"41","author":"E Alfaro-Arnedo","year":"2022","unstructured":"Alfaro-Arnedo E, Lopez IP, Pineiro-Hermida S, Canalejo M, Gotera C, Sola JJ, et al. IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression. Oncogene. 2022;41:3625\u201339.","journal-title":"Oncogene"},{"key":"4086_CR37","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1242\/jcs.01423","volume":"117","author":"H Muramatsu","year":"2004","unstructured":"Muramatsu H, Zou P, Suzuki H, Oda Y, Chen GY, Sakaguchi N, et al. alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci. 2004;117:5405\u201315.","journal-title":"J Cell Sci"},{"key":"4086_CR38","doi-asserted-by":"publisher","first-page":"38804","DOI":"10.18632\/oncotarget.5661","volume":"6","author":"M Wobus","year":"2015","unstructured":"Wobus M, Bornhauser M, Jacobi A, Krater M, Otto O, Ortlepp C, et al. Association of the EGF-TM7 receptor CD97 expression with FLT3-ITD in acute myeloid leukemia. Oncotarget. 2015;6:38804\u201315.","journal-title":"Oncotarget"},{"key":"4086_CR39","doi-asserted-by":"publisher","first-page":"1231916","DOI":"10.3389\/fimmu.2023.1231916","volume":"14","author":"A Mac Donald","year":"2023","unstructured":"Mac Donald A, Guipouy D, Lemieux W, Harvey M, Bordeleau LJ, Guay D, et al. KLRC1 knockout overcomes HLA-E-mediated inhibition and improves NK cell antitumor activity against solid tumors. Front Immunol. 2023;14:1231916.","journal-title":"Front Immunol"},{"key":"4086_CR40","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-017-2023-x","volume":"66","author":"W van der Touw","year":"2017","unstructured":"van der Touw W, Chen HM, Pan PY, Chen SH. LILRB receptor-mediated regulation of myeloid cell maturation and function. Cancer Immunol Immunother. 2017;66:1079\u201387.","journal-title":"Cancer Immunol Immunother"},{"key":"4086_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blade","year":"2022","unstructured":"Blade J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45.","journal-title":"Blood Cancer J"},{"key":"4086_CR42","doi-asserted-by":"publisher","first-page":"e40049e0","DOI":"10.1097\/01.HS9.0000970640.40049.e0","volume":"7","author":"Y Tao","year":"2023","unstructured":"Tao Y, Jin SW, Wang Y, Tang SJ, Liu YF, Xu J, et al. The effects of extramedullary disease on outcomes of patients with newly diagnosed multiple myeloma. HemaSphere. 2023;7:e40049e0.","journal-title":"HemaSphere."},{"key":"4086_CR43","first-page":"890","volume":"103","author":"N Gagelmann","year":"2018","unstructured":"Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103:890\u20137.","journal-title":"Haematologica"},{"key":"4086_CR44","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3324\/haematol.2019.219295","volume":"105","author":"M Beksac","year":"2020","unstructured":"Beksac M, Seval GC, Kanellias N, Coriu D, Rosinol L, Ozet G, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2020;105:201\u20138.","journal-title":"Haematologica"},{"key":"4086_CR45","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.3390\/cancers14246106","volume":"14","author":"X Yue","year":"2022","unstructured":"Yue X, He D, Zheng G, Yang Y, Han X, Li Y, et al. Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients. Cancers (Basel). 2022;14:6016. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9776506\/.","journal-title":"Cancers (Basel)"},{"key":"4086_CR46","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.13383","volume":"169","author":"M Weinstock","year":"2015","unstructured":"Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015;169:851\u20138.","journal-title":"Br J Haematol"},{"key":"4086_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.6004\/jnccn.2018.7079","volume":"17","author":"S Leng","year":"2019","unstructured":"Leng S, Chen Y, Tsai WY, Bhutani D, Hillyer GC, Lim E, et al. Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma. J Natl Compr Canc Netw. 2019;17:22\u20138.","journal-title":"J Natl Compr Canc Netw"},{"key":"4086_CR48","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie B, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19:370\u201381.","journal-title":"Lancet Oncol"},{"key":"4086_CR49","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos E, Zamagni E, Lentzsch S, Drake MT, Garcia-Sanz R, Abildgaard N, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021;22:e119\u201330.","journal-title":"Lancet Oncol"},{"key":"4086_CR50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.clml.2014.12.013","volume":"15","author":"S Deng","year":"2015","unstructured":"Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y, et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015;15:286\u201391.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4086_CR51","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-020-01060-w","volume":"35","author":"J Liu","year":"2021","unstructured":"Liu J, Hu X, Jia Y, Lu J, Lee JH, Kim K, et al. Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). Leukemia. 2021;35:1797\u2013802.","journal-title":"Leukemia"},{"key":"4086_CR52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.12255","volume":"92","author":"F Zagouri","year":"2014","unstructured":"Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, et al. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. Eur J Haematol. 2014;92:308\u201312.","journal-title":"Eur J Haematol"},{"key":"4086_CR53","doi-asserted-by":"publisher","first-page":"6297","DOI":"10.1158\/0008-5472.CAN-18-1045","volume":"78","author":"TF Eleveld","year":"2018","unstructured":"Eleveld TF, Schild L, Koster J, Zwijnenburg DA, Alles LK, Ebus ME, et al. RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma. Cancer Res. 2018;78:6297\u2013307.","journal-title":"Cancer Res"},{"key":"4086_CR54","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.22.00690","volume":"41","author":"JQ Mi","year":"2023","unstructured":"Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, et al. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed\/Refractory Multiple Myeloma (CARTIFAN-1). J Clin Oncol. 2023;41:1275\u201384.","journal-title":"J Clin Oncol"},{"key":"4086_CR55","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116:9543\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4086_CR56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15:86.","journal-title":"J Hematol Oncol"},{"key":"4086_CR57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","volume":"17","author":"J Xu","year":"2024","unstructured":"Xu J, Wang BY, Yu SH, Chen SJ, Yang SS, Liu R, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial. J Hematol Oncol. 2024;17:23","journal-title":"J Hematol Oncol"},{"key":"4086_CR58","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Usmani SZ. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance. Front Immunol. 2018;9:2134.","journal-title":"Front Immunol"},{"key":"4086_CR59","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/s41375-023-01983-0","volume":"37","author":"D Chemlal","year":"2023","unstructured":"Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N, et al. EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma. Leukemia. 2023;37:1925\u20138.","journal-title":"Leukemia"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04086-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04086-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04086-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:17:01Z","timestamp":1746191821000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04086-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4086"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04086-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"23 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Internal Review Board (IRB) of Ruijin Hospital approved this study (Approval number 2014\u2013059). Informed consent was obtained from all study participants. The study was carried out following the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}